N-acetyltransferase 2 and bladder cancer
Author Information
Author(s): Green J, Banks E, Berrington A, Darby S, Deo H, Newton R
Primary Institution: Imperial Cancer Research Fund Cancer Epidemiology Unit, University of Oxford
Hypothesis
Does genetic polymorphism of N-acetyltransferase 2 influence susceptibility to bladder cancer related to smoking or occupational exposure?
Conclusion
The evidence suggests that the NAT2 slow acetylator phenotype may be linked to a slight increase in bladder cancer risk, but publication bias complicates the interpretation.
Supporting Evidence
- The review included 21 case-control studies with a total of 2700 cases and 3426 controls.
- NAT2 slow acetylator phenotype may be associated with a small increase in bladder cancer risk.
- Only five studies reported results separately for smokers and non-smokers.
Takeaway
Some people might be more likely to get bladder cancer if they have a certain gene and smoke or work with harmful chemicals, but we need more studies to be sure.
Methodology
Review of 21 published case-control studies on NAT2 polymorphism and bladder cancer risk.
Potential Biases
Potential publication bias affecting the interpretation of results.
Limitations
The possibility of selective publication and insufficient evidence to assess joint effects.
Participant Demographics
2700 cases and 3426 controls from various studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website